“CM101 — An Anti-Pathoangiogenic Agent: Pre-Clinical and Clinical Experiences”
The pathophysiology of Group B Streptococcal (GBS) disease depends on the age of the neonate infected. Neonates infected at birth by GBS colonizing the birth canal may be diagnosed with early-onset disease. The symptoms are respiratory distress and cardiovascular shock (Baker and Edwards, 1995) and the gravity may vary from asymptomatic to lethal. In infants older than 1 week, late-onset disease is often associated with meningitis. GBS rarely affects normal adults, but may present in old adults with impaired peripheral circulation (diabetics) or with a compromised immune system due to cancer or other debilitating disease (Farley, Harvey, Stull, Smith, Schuchat, Wenger, and Stephens, 1993).
KeywordsComplement Receptor Type Tumor Neovasculature Young Lamb Minute Time Point Cardiovascular Shock
Unable to display preview. Download preview PDF.
- Baker, C.J. and Edwards M.S., 1995, Group B streptococcal infections, in: Infectious Diseases of the Fetus and Newborn Infant, 4th Edition (Remington, J.S. and Klein, J.O., eds.), pp. 980–1054, W.B. Saunders Co., Philadelphia, PA.Google Scholar
- DeVore, R., Johnson, D.R., Hellerqvist, C., Wakefield, G., Browning, P., Page, D., Sundeil, H., and Johnson, D.H., 1996, A phase I study of the anti-neovascularization drug CM101, Proceedings of ASCO Meeting, 15:1558.Google Scholar
- DeVore, R.F., Hellerqvist, C.G., Wakefield, G.B., Wamil, B.D., Thurman, G.B., Minton, P.A., Sundell, H.W., Yan, H.-P., Carter, C.E., Wang, Y.-F., York, G.E., Zhang, M.-H., and Johnson, D.H., 1997, A phase I study of the antineovascularization drug CM101, J. Clin. Can. Res. 3:365–372.Google Scholar
- Hellerqvist, C.G., 1991, Therapeutic agent and method of inhibiting vascularization of tumors, U.S. Patent 5,010,062.Google Scholar
- Hellerqvist, C.G., Wang, E., Wamil, B.D., Price, J.O., Yan, H.-P., Carter, C.E., Wang, Y-F., DeVore, R.F., Johnson, D.H., and Lloyd, 1997, Evidence of induced apoptosis in cancer patients treated with CM101, Proceedings of ASCO Annual Meeting.Google Scholar
- Vetvicka, V., Thornton, B.P., and Ross, G.D., 1996, Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells, J. Clin. Invest. 98(1):50–61.PubMedCrossRefGoogle Scholar
- Wamil, B.D., Abramovitch, R., Wang, E., Neeman, M., Hellerqvist, C.G., 1997, CMI01 Inhibits VEGF Induced Tumor Neovascularization as Determined by MRI and RT-PCR, Proceedings of the 88th Annual American Association for Cancer Research Meeting.Google Scholar
- Wamil, B.D., Thurman, G.B., DeVore, R.F., Wakefield, G, Johnson, D.H., and Hellerqvist, C.G., 1997, Soluble E-Selectin in cancer patients as a marker of the therapeutic efficacy of CM101, a tumor inhibiting agent, evaluated in phase I clinical trial. J. Can. Res. Clin. Oncol. 123(3):173–179.CrossRefGoogle Scholar